Navigation Links
Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert

DALLAS Dec. 24, 2008 Anxiety disorders in children and adolescents should be recognized and treated to prevent educational underachievement and adult substance abuse, anxiety disorders and depression, says a nationally recognized child psychiatrist from UT Southwestern Medical Center.

In an editorial appearing in the Dec. 25 issue of New England Journal of Medicine, Dr. Graham Emslie, professor of psychiatry and pediatrics at UT Southwestern, urges awareness that children need to be treated for anxiety disorders and recommends that related empirical evidence be integrated into treatment guidelines.

"Anxiety disorders may cause children to avoid social situations and age-appropriate developmental milestones," said Dr. Emslie. "Further, the avoidance cycle can lead to less opportunity to develop social skills necessary for success later in life. Treatment would help children learn healthy coping skills."

Up to 20 percent of children and adolescents are affected by persistent and excessive worry that can manifest as generalized anxiety disorder, separation anxiety disorder and social phobia. Research has shown that failure to identify these disorders early leads to educational underachievement and increased rates of anxiety disorders, depression and substance abuse later in life.

Only with the adaptation of the Diagnostic and Statistical Manual of Mental Disorders 4th edition did the mental health community recognize that adult anxiety disorders have origins in childhood, wrote Dr. Emslie, the first psychiatrist to demonstrate that antidepressants are effective in depressed children and adolescents.

Anxiety disorders in children are frequently unrecognized because they may only report physical aches and may be unable to verbalize "worry" or "fear," said Dr. Emslie, chief of child and adolescent psychiatry at Children's Medical Center Dallas.

The editorial accompanies a study in the same issue of the journal by senior author John Walkup of Johns Hopkins Medical Institute. The pivotal research, which was conducted at seven medical institutions across the U.S., was the first study to directly compare medication treatment, cognitive behavioral therapy that examines thinking patterns in order to modify behavior, and the combination of both treatments in children and teens with anxiety disorders. The results showed that antidepressant medications and cognitive behavioral therapy were equally effective treatments for anxiety and that the combination of both treatments was most effective.

Dr. Emslie said he hopes future studies will build on this work to determine what type to treatment is best for individual patients.

"Partial treatment is not adequate," he said. "If children aren't treated to the point of complete remission, they are likely to relapse. It's imperative that we help children overcome their anxiety disorders for their own lifetime good."


Contact: LaKisha Ladson
UT Southwestern Medical Center

Related medicine news :

1. Yeast mimics severity of mutations leading to fatal childhood illness
2. UCSF receives $24.4 million to fight early childhood cavities
3. Childhood Obesity May Cause Thyroid Problems
4. Antacid Medication in Pregnancy May Increase Childhood Asthma
5. More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer
6. New partnership to foster healthier food habits in early childhood
7. Video: Childhood Influenza Immunization Coalition Supports Second Annual Childrens Flu Vaccination Day
8. Childhood Constipation Carries a Big Price Tag
9. Gene Behind Childhood Anemias Found
10. Adult survivors of childhood leukemia have lower bone mineral density, study finds
11. Siskin Center for Child and Family Research to Focus on Early Childhood Development and Special Education
Post Your Comments:
Related Image:
Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: